vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

Reuters

05-20

vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536063770"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536063770\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536063770?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536063770","market":"nz","top_or_hot":-1,"title":"vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL7nzy6K:1","article_id":"2536063770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536063770","pubTimestamp":1747686303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTVT":"vTv Therapeutics Inc."},"translate_title":"vTv Therapeutics重新启动Cadisegliatin的3期试验，这是一种有前途的1型糖尿病口服辅助疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":0.9},"content_text":"vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes\n    \n\nvTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-25-000032), on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}